Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS)

Jessica Mandrioli, Valeria Crippa, Cristina Cereda, Valentina Bonetto, Elisabetta Zucchi, Annalisa Gessani, Mauro Ceroni, Adriano Chio, Roberto D'Amico, Maria Rosaria Monsurrò, Nilo Riva, Mario Sabatelli, Vincenzo Silani, Isabella Laura Simone, Gianni Sorarù, Alessandro Provenzani, Vito Giuseppe D'Agostino, Serena Carra, Angelo Poletti, Jessica Mandrioli, Valeria Crippa, Cristina Cereda, Valentina Bonetto, Elisabetta Zucchi, Annalisa Gessani, Mauro Ceroni, Adriano Chio, Roberto D'Amico, Maria Rosaria Monsurrò, Nilo Riva, Mario Sabatelli, Vincenzo Silani, Isabella Laura Simone, Gianni Sorarù, Alessandro Provenzani, Vito Giuseppe D'Agostino, Serena Carra, Angelo Poletti

Abstract

Introduction: Disruptions of proteasome and autophagy systems are central events in amyotrophic lateral sclerosis (ALS) and support the urgent need to find therapeutic compounds targeting these processes. The heat shock protein B8 (HSPB8) recognises and promotes the autophagy-mediated removal of misfolded mutant SOD1 and TDP-43 fragments from ALS motor neurons (MNs), as well as aggregating species of dipeptides produced in C9ORF72-related diseases. In ALS-SOD1 mice and in human ALS autopsy specimens, HSPB8 is highly expressed in spinal cord MNs that survive at the end stage of disease. Moreover, the HSPB8-BAG3-HSP70 complex maintains granulostasis, which avoids conversion of dynamic stress granules (SGs) into aggregation-prone assemblies. We will perform a randomised clinical trial (RCT) with colchicine, which enhances the expression of HSPB8 and of several autophagy players, blocking TDP-43 accumulation and exerting crucial activities for MNs function.

Methods and analysis: Colchicine in amyotrophic lateral sclerosis (Co-ALS) is a double-blind, placebo-controlled, multicentre, phase II RCT. ALS patients will be enrolled in three groups (placebo, colchicine 0.01 mg/day and colchicine 0.005 mg/day) of 18 subjects treated with riluzole; treatment will last 30 weeks, and follow-up will last 24 weeks. The primary aim is to assess whether colchicine decreases disease progression as measured by ALS Functional Rating Scale - Revised (ALSFRS-R) at baseline and at treatment end. Secondary aims include assessment of (1) safety and tolerability of Colchicine in patiets with ALS; (2) changes in cellular activity (autophagy, protein aggregation, and SG and exosome secretion) and in biomarkers of disease progression (neurofilaments); (3) survival and respiratory function and (4) quality of life. Preclinical studies with a full assessment of autophagy and neuroinflammation biomarkers in fibroblasts, peripheral blood mononuclear cells and lymphoblasts will be conducted in parallel with clinic assessment to optimise time and resources.

Ethics and dissemination: The study protocol was approved by the Ethics Committee of Area Vasta Emilia Nord and by Agenzia Italiana del Farmaco (EUDRACT N.2017-004459-21) based on the Declaration of Helsinki. This research protocol was written without patient involvement. Patients' association will be involved in disseminating the study design and results. Results will be presented during scientific symposia or published in scientific journals.

Trial registration number: EUDRACT 2017-004459-21; NCT03693781; Pre-results.

Keywords: HSPB8; amyotrophic lateral sclerosis; autophagy; colchicine; randomized clinical trial; stress granules.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Design of the study. FS, progression rate; IVRS, interactive voice response system; IWRS, interactive web response system.

References

    1. Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism. Nature 2016;539:197–206. 10.1038/nature20413
    1. Calvo A, Moglia C, Lunetta C, et al. . Factors predicting survival in ALS: a multicenter Italian study. J Neurol 2017;264:54–63. 10.1007/s00415-016-8313-y
    1. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012:CD001447 10.1002/14651858.CD001447.pub3
    1. Writing Group Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505–12. 10.1016/S1474-4422(17)30115-1
    1. Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol 2014;13:1127–38. 10.1016/S1474-4422(14)70129-2
    1. van den Berg LH, Sorenson E, Gronseth G, et al. . Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology 2019;92:e1610–23. 10.1212/WNL.0000000000007242
    1. Thomas M, Alegre-Abarrategui J, Wade-Martins R. RNA dysfunction and aggrephagy at the centre of an amyotrophic lateral sclerosis/frontotemporal dementia disease continuum. Brain 2013;136:1345–60. 10.1093/brain/awt030
    1. Iguchi Y, Eid L, Parent M, et al. . Exosome secretion is a key pathway for clearance of pathological TDP-43. Brain 2016;139:3187–201. 10.1093/brain/aww237
    1. Buchan JR, Kolaitis RM, Taylor JP, et al. . Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function. Cell 2013;153:1461–74. 10.1016/j.cell.2013.05.037
    1. Chitiprolu M, Jagow C, Tremblay V, et al. . A complex of C9ORF72 and p62 uses arginine methylation to eliminate stress granules by autophagy. Nat Commun 2018;9:2794 10.1038/s41467-018-05273-7
    1. Zhao W, Beers DR, Bell S, et al. . TDP-43 activates microglia through NF-κB and NLRP3 inflammasome. Exp Neurol 2015;273:24–35. 10.1016/j.expneurol.2015.07.019
    1. Cadwell K. Crosstalk between autophagy and inflammatory signalling pathways: balancing defence and homeostasis. Nat Rev Immunol 2016;16:661–75. 10.1038/nri.2016.100
    1. Crippa V, D’Agostino VG, Cristofani R, et al. . Transcriptional induction of the heat shock protein B8 mediates the clearance of misfolded proteins responsible for motor neuron diseases. Sci Rep 2016;6:22827 10.1038/srep22827
    1. Carra S, Seguin SJ, Lambert H, et al. . HspB8 chaperone activity toward poly(Q)-containing proteins depends on its association with Bag3, a stimulator of macroautophagy. J Biol Chem 2008;283:1437–44. 10.1074/jbc.M706304200
    1. Crippa V, Sau D, Rusmini P, et al. . The small heat shock protein B8 (HspB8) promotes autophagic removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS). Hum Mol Genet 2010;19:3440–56. 10.1093/hmg/ddq257
    1. Rusmini P, Cristofani R, Galbiati M, et al. . The Role of the Heat Shock Protein B8 (HSPB8) in Motoneuron Diseases. Front Mol Neurosci 2017;10:176 10.3389/fnmol.2017.00176
    1. Anagnostou G, Akbar MT, Paul P, et al. . Vesicle associated membrane protein B (VAPB) is decreased in ALS spinal cord. Neurobiol Aging 2010;31:969–85. 10.1016/j.neurobiolaging.2008.07.005
    1. Cristofani R, Crippa V, Rusmini P, et al. . Inhibition of retrograde transport modulates misfolded protein accumulation and clearance in motoneuron diseases. Autophagy 2017;13:1280–303. 10.1080/15548627.2017.1308985
    1. Crippa V, Cicardi ME, Ramesh N, et al. . The chaperone HSPB8 reduces the accumulation of truncated TDP-43 species in cells and protects against TDP-43-mediated toxicity. Hum Mol Genet 2016;25:3908–24. 10.1093/hmg/ddw232
    1. Cristofani R, Crippa V, Vezzoli G, et al. . The small heat shock protein B8 (HSPB8) efficiently removes aggregating species of dipeptides produced in C9ORF72-related neurodegenerative diseases. Cell Stress Chaperones 2018;23:1–12. 10.1007/s12192-017-0806-9
    1. Huang CC, Bose JK, Majumder P, et al. . Metabolism and mis-metabolism of the neuropathological signature protein TDP-43. J Cell Sci 2014;127:3024–38. 10.1242/jcs.136150
    1. Cicardi ME, Cristofani R, Rusmini P, et al. . Tdp-25 Routing to Autophagy and Proteasome Ameliorates its Aggregation in Amyotrophic Lateral Sclerosis Target Cells. Sci Rep 2018;8:12390 10.1038/s41598-018-29658-2
    1. Carra S, Seguin SJ, Landry J. HspB8 and Bag3: a new chaperone complex targeting misfolded proteins to macroautophagy. Autophagy 2008;4:237–9. 10.4161/auto.5407
    1. Ganassi M, Mateju D, Bigi I, et al. . A Surveillance Function of the HSPB8-BAG3-HSP70 Chaperone Complex Ensures Stress Granule Integrity and Dynamism. Mol Cell 2016;63:796–810. 10.1016/j.molcel.2016.07.021
    1. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum 2009;38:411–9. 10.1016/j.semarthrit.2008.08.006
    1. Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of action of colchicine in the treatment of gout. Clin Ther 2014;36:1465–79. 10.1016/j.clinthera.2014.07.017
    1. Brooks BR, Miller RG, Swash M, et al. . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293–9. 10.1080/146608200300079536
    1. Chiò A, Calvo A, Moglia C, et al. . Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2011;82:740–6. 10.1136/jnnp.2010.235952
    1. Kimura F, Fujimura C, Ishida S, et al. . Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 2006;66:265–7. 10.1212/01.wnl.0000194316.91908.8a
    1. Sabatelli M, Zollino M, Conte A, et al. . Primary fibroblasts cultures reveal TDP-43 abnormalities in amyotrophic lateral sclerosis patients with and without SOD1 mutations. Neurobiol Aging 2015;36:2005.e5–2005.e13. 10.1016/j.neurobiolaging.2015.02.009
    1. De Marco G, Lomartire A, Calvo A, et al. . Monocytes of patients with amyotrophic lateral sclerosis linked to gene mutations display altered TDP-43 subcellular distribution. Neuropathol Appl Neurobiol 2017;43:133–53. 10.1111/nan.12328
    1. Pansarasa O, Bordoni M, Drufuca L, et al. . Lymphoblastoid cell lines as a model to understand amyotrophic lateral sclerosis disease mechanisms. Dis Model Mech 2018;11:dmm031625 10.1242/dmm.031625
    1. Gagliardi S, Zucca S, Pandini C, et al. . Long non-coding and coding RNAs characterization in Peripheral Blood Mononuclear Cells and Spinal Cord from Amyotrophic Lateral Sclerosis patients. Sci Rep 2018;8:2378 10.1038/s41598-018-20679-5
    1. Ching JK, Elizabeth SV, Ju JS, et al. . mTOR dysfunction contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion body myopathy. Hum Mol Genet 2013;22:1167–79. 10.1093/hmg/dds524
    1. Sproviero D, La Salvia S, Giannini M, et al. . Pathological proteins are transported by extracellular vesicles of sporadic amyotrophic lateral sclerosis patients. Front Neurosci 2018;12:487 10.3389/fnins.2018.00487
    1. Kaufmann P, Levy G, Thompson JL, et al. . The ALSFRSr predicts survival time in an ALS clinic population. Neurology 2005;64:38–43. 10.1212/01.WNL.0000148648.38313.64
    1. Castrillo-Viguera C, Grasso DL, Simpson E, et al. . Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler 2010;11:178–80. 10.3109/17482960903093710
    1. Kollewe K, Mauss U, Krampfl K, et al. . ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci 2008;275:69–73. 10.1016/j.jns.2008.07.016

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅